lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Malignant Carcinoid Syndrome
Conditions
Malignant Carcinoid Syndrome
Trial Timeline
Jul 1, 2004 → Oct 1, 2004
NCT ID
NCT00092287About lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)
lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue) is a phase 3 stage product being developed by Ipsen for Malignant Carcinoid Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00092287. Target conditions include Malignant Carcinoid Syndrome.
What happened to similar drugs?
5 of 20 similar drugs in Malignant Carcinoid Syndrome were approved
Approved (5) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00092287 | Phase 3 | Terminated |
Competing Products
20 competing products in Malignant Carcinoid Syndrome